Aurobindo Pharma has informed stock exchanges that its subsidiary, TheraNym Biologics, has signed an additional product schedule with Merck Sharpe & Dohme Singapore Trading (MSD), further expanding their existing contract manufacturing partnership that began in May 2024. 

Under the new agreement, TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility, named Unit 2, with an aggregate 60,000-litre bioreactor capacity.

The facility will include advanced downstream purification infrastructure to manufacture biologic drug substances for both domestic and international markets. 

As part of the expansion, TheraNym will invest approximately $150 million to $175 million in the new unit. The company said it will build the facility, manufacture the products, and supply them to MSD under the arrangement, strengthening Aurobindo’s biologics contract manufacturing footprint. 

The latest move deepens Aurobindo Pharma’s strategic push into biologics manufacturing and reinforces its long-term CMO relationship with MSD, as demand for large-scale mammalian cell culture capacity continues to rise globally.